Author:
Coli Antonella,Asa Sylvia L,Fadda Guido,Scannone Domenico,Chiloiro Sabrina,De Marinis Laura,Lauretti Liverana,Ranelletti Franco O,Lauriola Libero
Abstract
BackgroundKi-67 labeling index (LI) is currently regarded as a useful prognostic marker of pituitary adenoma (PA) clinical behavior, although its relevance as a reliable clinical indicator is far from being universally accepted, since both validations and criticisms are found in the literature. Minichromosome maintenance 7 (MCM7), a cell-cycle regulator protein, has been recently proposed as a marker of tumor aggressiveness in tumors from many sites, including the CNS. Therefore, we evaluated MCM7, in comparison to Ki-67, as a potential marker of clinical outcome in PA.Design and methodsIn this single-institution retrospective study, 97 patients with PA (23 ACTH, 12 GH, 29 PRL, 10 FSH/LH, and 23 non-secreting adenomas) were recruited and the prognostic value of both MCM7 and Ki-67 was evaluated by immunohistochemical techniques. In addition, p53 nuclear expression and mitotic index were also evaluated.ResultsTwenty-six of the 97 PA patients recurred during the follow-up period. Cox's regression analysis showed that high nuclear expression of MCM7 LI, unlike Ki-67 LI, was directly associated with a higher (7.7-fold) risk of recurrence/progression. Kaplan–Meier analysis of recurrence/progression-free survival curves revealed that patients with high MCM7 LI (≥15%) had a shorter recurrence/progression-free survival than those with low MCM7 LI (<15%). Moreover, among patients with invasive tumors, high MCM7 LI identified those with the highest risk of recurrence/progression.ConclusionsData from this study suggest that MCM7 is a prognostic marker of clinical outcome in PA patients, more reliable and informative than Ki-67.
Subject
Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism
Reference49 articles.
1. Asa SL. Tumors of the pituitary gland. Fascicle 15, 4th Series. In The Atlas of Tumor Pathology. pp 55–172. Washington DC: Armed Forces Institute of Pathology, 2011
2. Clinicopathological Correlations in Pituitary Adenomas
3. Lloyd RV, Kovacs K, Young WF Jr, Farrell WE, Asa SL, Trouillas J, Kontogeorgos G, Sano T, Scheithauer BW, Horvath E. Pituitary tumours: Introduction. In World Health Pathology and Genetics of Tumours of Endocrine Organs, ch. 1, pp 10–13. Eds RA DeLellis, RV Lloyd, PU Heitz & C Eng. Lyon: IARC Press, 2004
4. Proliferation Index of Nonfunctioning Pituitary Adenomas: Correlations with Clinical Characteristics and Long-term Follow-up Results
5. P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas;Hentschel;Canadian Journal of Neurological Sciences,2003
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献